Moderna (MRNA) Beat Revenue Views, Is The Stock Now Too Expensive?Simplywall·3 hours agoMRNA+5.21%MRNX+10.85%
Dell Upgraded, Tesla Downgraded: Updated Rankings on Top Blue-Chip StocksInvestorPlace·Jul 27 at 08:24 AMAXP+1.57%DELL+10.60%
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial NewsSimplywall·Jul 24 at 04:14 AMMRNA+5.21%MRNX+10.85%
Earnings Preview: What To Expect From Moderna’s ReportBarchart Option·Jul 23 at 06:48 AMMRNA+5.21%MRNX+10.85%
Moderna (MRNA) Adds Finance Veteran To Its Board, Is The Stock Fully Valued?Simplywall·Jul 22 at 08:14 AMMRNA+5.21%MRNX+10.85%
FairJourney Bio Announces Scientific Program and Leadership for The Antibody Series 2026MorningStar·Jul 21 at 04:04 AMMRNA+5.21%MRNX+10.85%
Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination FeeTradingView·Jul 16 at 06:33 AMABUS+1.75%MRNA+5.21%
Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technologyPUBT·Jul 16 at 06:32 AMABUS+1.75%MRNA+5.21%
Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumorsPUBT·Jul 16 at 06:05 AMMRNA+5.21%MRNX+10.85%
